New aspects for the treatment of cardiac diseases based on the diversity of functional controls on cardiac muscles: effects of targeted disruption of the type 5 adenylyl cyclase gene

Journal of Pharmacological Sciences

Volumn 109, Issue 3, 2009, Pages 354-359

  Okumura, Satoshi ^a   Suzuki, Sayaka ^a   Ishikawa, Yoshihiro ^a,b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Autonomic nervous system; Cardiac adenylyl cyclase; Cardiac disease; Heart failure; Knockout mouse; Longevity

Indexed keywords

ADENYLATE CYCLASE; ADENYLATE CYCLASE TYPE 5; CYCLIC AMP; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN BCL 2; RAF PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ENZYME ACTIVITY; ENZYME REGULATION; GENE DISRUPTION; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE OVERLOAD; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; ANIMALS; APOPTOSIS; CALCIUM; CYCLIC AMP; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; HEART FAILURE; HUMANS; ISOENZYMES; MICE; MICE, KNOCKOUT; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION;

EID: 67249102591     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08R26FM     Document Type: Short Survey

References (23)

1. Taussig R, Gilman AG. Mammalian membrane-bound adenylyl cyclases. J Biol Chem. 1995;270:1-4.
2. Scott JD. Cyclic nucleotide-dependent protein kinases. Pharmacol Ther. 1991;50:123-145.
3. Hanoune J, Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol. 2001;41:145-174.
4. Ishikawa Y, Homcy CJ. The adenylyl cyclases as integrators of transmembrane signal transduction. Circ Res. 1997;80:297-304. (Pubitemid 27093342)
5. Ishikawa Y, Katsushika S, Chen L, Halnon NJ, Kawabe J, Homcy CJ. Isolation and characterization of a novel cardiac adenylylcyclase cDNA. J Biol Chem. 1992;267:13553-13557.
6. Katsushika S, Chen L, Kawabe J, Nilakantan R, Halnon NJ, Homcy CJ, et al. Cloning and characterization of a sixth adenylyl cyclase isoform: types V and VI constitute a subgroup within the mammalian adenylyl cyclase family. Proc Natl Acad Sci USA. 1992;89:8774-8778.
7. Premont RT, Chen J, Ma HW, Ponnapalli M, Iyengar R. Two members of a widely expressed subfamily of hormone-stimulated adenylyl cyclases. Proc Natl Acad Sci USA. 1992;89:9809-9813.
8. Yoshimura M, Cooper DM. Cloning and expression of a Ca2+- inhibitable adenylyl cyclase from NCB-20 cells. Proc Natl Acad Sci USA. 1992;89:6716-6720.
9. Okumura S, Kawabe J, Yatani A, Takagi G, Lee MC, Hong C, et al. Type 5 adenylyl cyclase disruption alters not only sympathetic but also parasympathetic and calcium-mediated cardiac regulation. Circ Res. 2003;93:364-371.
10. Tobise K, Ishikawa Y, Holmer SR, Im MJ, Newell JB, Yoshie H, et al. Changes in type VI adenylyl cyclase isoform expression correlate with a decreased capacity for cAMP generation in the aging ventricle. Circ Res. 1994;74:596-603. (Pubitemid 24088520)
11. Espinasse I, Iourgenko V, Defer N, Samson F, Hanoune J, Mercadier JJ. Type V, but not type VI, adenylyl cyclase mRNA accumulates in the rat heart during ontogenic development. Correlation with increased global adenylyl cyclase activity. J Mol Cell Cardiol. 1995;27:1789-1795.
12. Mahdavi V, Chambers AP, Nadal-Ginard B. Cardiac a- and /?- myosin heavy chain genes are organized in tandem. Proc Natl Acad Sci USA. 1984;81:2626-2630.
13. Okumura S, Takagi G, Kawabe J, Yang G, Lee MC, Hong C, et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci USA. 2003;100:9986-9990. (Pubitemid 37087055)
14. Okumura S, Vatner DE, Kurotani R, Bai Y, Gao S, Yuan, Z, et al. Disruption of type 5 adenylyl cyclase enhances desensitization of cyclic adenosine monophosphate signal and increases Akt signal with chronic catecholamine stress. Circulation. 2007;116:1776-1783. (Pubitemid 350287102)
15. Yan L, Vatner DE, O'Connor JP, Ivessa A, Ge H, Chen W, et al. Type 5 adenylyl cyclase disruption increases longevity and protects against stress. Cell. 2007;130:247-258. (Pubitemid 47081133)
16. Okumura S, Tsunematsu T, Bai Y, Jiao Q, Ono S, Suzuki S, et al. Type 5 adenylyl cyclase plays a major role in stabilizing heart rate in response to microgravity induced by parabolic flight. J Appl Physiol. 2008;105:173-179.
17. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J, et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell. 1999;97:189-198. (Pubitemid 29194270)
18. Yamauchi-Takihara K, Kishimoto T. A novel role for STAT3 in cardiac remodeling. Trends Cardiovasc Med. 2000;10:298-303.
19. Uozumi H, Hiroi Y, Zou Y, Takimoto E, Toko H, Niu P, et al. gp130 plays a critical role in pressure overload-induced cardiac hypertrophy. J Biol Chem. 2001;276:23115-23119.
20. Misao J, Hayakawa Y, Ohno M, Kato S, Fujiwara T, Fujiwara H. Expression of bcl-2 protein, an inhibitor of apoptosis, and Bax, an accelerator of apoptosis, in ventricular myocytes of human hearts with myocardial infarction. Circulation. 1996;94:1506-1512. (Pubitemid 26320251)
21. Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. Role of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med. 1972;287:781-787.
22. Iwatsubo K, Minamisawa S, Tsunematsu T, Nakagome M, Toya Y, Tomlinson JE, et al. Direct inhibition of type 5 adenylyl cyclase prevents myocardiac apoptosis without functional deteriaration. J Biol Chem. 2004;279:40938-40945. (Pubitemid 39287693)
23. Ishikawa Y. Isoform-targeted regulation of cardiac adenylyl cyclase. J Cardiovasc Pharmacol. 2003;41:Suppl 1:S1-S4.